Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company.
A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Hyliion Holdings Corporation | Thomas Healy | Director, Chief Executive Officer, Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jun 2026 | 2,500,000 | 32,812,262 | - | 0 | Common Stock | |
| EchoStar Corp (Class A) | Charles W. Ergen | Director, CHAIRMAN, PRES and CEO, Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jun 2026 | 2,316,533 | 2,388,447 | - | - | Class B Common Stock | |
| EchoStar Corp (Class A) | Charles W. Ergen | Director, CHAIRMAN, PRES and CEO, Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jun 2026 | 2,316,533 | 14,483,467 | - | - | Class B Common Stock | |
| Navan Inc Ordinary Shares | Oren Zeev | Director, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 26 Jun 2026 | 1,576,676 | 12,613,415 | - | 0 | Class A Common Stock | |
| Navan Inc Ordinary Shares | Oren Zeev | Director, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 26 Jun 2026 | 1,576,676 | 14,190,091 | - | 0 | Class A Common Stock | |
| Navan Inc Ordinary Shares | Oren Zeev | Director, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 26 Jun 2026 | 1,082,303 | 9,740,729 | - | 0 | Class A Common Stock | |
| Clear Secure Inc (Class A) | Caryn Seidman Becker | Director, Chief Executive Officer, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 801,943 | 1,040,308 | - | 0 | Class A Common Stock | |
| Clear Secure Inc (Class A) | Caryn Seidman Becker | Director, Chief Executive Officer, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 801,943 | 1,603,888 | - | - | Performance Restricted Stock Units | |
| Schrodinger Inc | Richard A. Friesner | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jun 2026 | 679,373 | 679,373 (1%) | 1% | 0 | Common Stock | |
| Schrodinger Inc | Richard A. Friesner | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jun 2026 | 679,373 | 0 (0%) | 1% | 0 | Common Stock | |
| Roivant Sciences Ltd | Keith Manchester | Director | Sale of securities on an exchange or to another person at price $ 34.59 per share. | 26 Jun 2026 | 600,000 | 13,701,546 | - | 34.6 | 20,754,000 | Common Shares |
| Roivant Sciences Ltd | Daniel Gold | Director | Sale of securities on an exchange or to another person at price $ 34.59 per share. | 26 Jun 2026 | 600,000 | 13,701,546 | - | 34.6 | 20,754,000 | Common Shares |
| Navan Inc Ordinary Shares | Oren Zeev | Director, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 26 Jun 2026 | 567,965 | 1,135,930 | - | 0 | Class A Common Stock | |
| Navan Inc Ordinary Shares | Oren Zeev | Director, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 26 Jun 2026 | 567,965 | 567,965 | - | 0 | Class A Common Stock | |
| Jupiter Neurosciences Inc | Tomas J. Philipson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 536,428 | 536,428 | - | - | Stock Option (right to buy) | |
| Navan Inc Ordinary Shares | Oren Zeev | Director, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 26 Jun 2026 | 452,949 | 4,076,544 | - | 0 | Class A Common Stock | |
| Navan Inc Ordinary Shares | Oren Zeev | Director, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 26 Jun 2026 | 452,949 | 3,623,595 | - | 0 | Class A Common Stock | |
| LifeStance Health Grp Inc | Robert Bessler | Director | Sale of securities on an exchange or to another person at price $ 10.13 per share. | 26 Jun 2026 | 447,169 | 656,560 | - | 10.1 | 4,529,822 | Common Stock |
| LifeStance Health Grp Inc | Robert Bessler | Director | Sale of securities on an exchange or to another person at price $ 10.13 per share. | 26 Jun 2026 | 447,168 | 539,763 | - | 10.1 | 4,529,812 | Common Stock |
| Clear Secure Inc (Class A) | Caryn Seidman Becker | Director, Chief Executive Officer, Ten Percent Owner | Payment of exercise price or tax liability using portion of securities received from the company at price $ 55.17 per share. | 26 Jun 2026 | 443,475 | 596,833 | - | 55.2 | 24,466,516 | Class A Common Stock |
| Roivant Sciences Ltd | Keith Manchester | Director | Sale of securities on an exchange or to another person at price $ 34.07 per share. | 26 Jun 2026 | 325,000 | 14,501,546 | - | 34.1 | 11,072,750 | Common Shares |
| Roivant Sciences Ltd | Daniel Gold | Director | Sale of securities on an exchange or to another person at price $ 34.07 per share. | 26 Jun 2026 | 325,000 | 14,501,546 | - | 34.1 | 11,072,750 | Common Shares |
| Roivant Sciences Ltd | Keith Manchester | Director | Sale of securities on an exchange or to another person at price $ 33.92 per share. | 26 Jun 2026 | 300,783 | 14,826,546 | - | 33.9 | 10,202,559 | Common Shares |
| Roivant Sciences Ltd | Daniel Gold | Director | Sale of securities on an exchange or to another person at price $ 33.92 per share. | 26 Jun 2026 | 300,783 | 14,826,546 | - | 33.9 | 10,202,559 | Common Shares |
| Kymera Therapeutics Inc | Bruce Booth | Director | Sale of securities on an exchange or to another person at price $ 108.14 per share. | 26 Jun 2026 | 231,007 | 2,603,048 | - | 108.1 | 24,981,097 | Common Stock |
| Roivant Sciences Ltd | Keith Manchester | Director | Sale of securities on an exchange or to another person at price $ 35.45 per share. | 26 Jun 2026 | 200,000 | 1,748,403 | - | 35.5 | 7,090,000 | Common Shares |
| Roivant Sciences Ltd | Keith Manchester | Director | Sale of securities on an exchange or to another person at price $ 34.44 per share. | 26 Jun 2026 | 200,000 | 14,301,546 | - | 34.4 | 6,888,000 | Common Shares |
| Roivant Sciences Ltd | Daniel Gold | Director | Sale of securities on an exchange or to another person at price $ 34.44 per share. | 26 Jun 2026 | 200,000 | 14,301,546 | - | 34.4 | 6,888,000 | Common Shares |
| Dyne Therapeutics Inc | Jason P. Rhodes | Director | Sale of securities on an exchange or to another person at price $ 21.28 per share. | 26 Jun 2026 | 162,954 | 4,579,456 | - | 21.3 | 3,467,661 | Common Stock |
| Inhibikase Therapeutics Inc | Dennis N. Berman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 155,000 | 155,000 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Roberto Bellini | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 155,000 | 155,000 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Amit D. Munshi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 155,000 | 155,000 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Vincent E. Aurentz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 155,000 | 155,000 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | Arvind Kush | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 155,000 | 155,000 | - | - | Stock Option (Right to Buy) | |
| Inhibikase Therapeutics Inc | David Canner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 155,000 | 155,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Sale of securities on an exchange or to another person at price $ 21.14 per share. | 26 Jun 2026 | 154,768 | 221,278 (0%) | 0% | 21.1 | 3,271,796 | Common Stock |
| Guardant Health Inc | AmirAli Talasaz | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 143,028 | 28,997 | - | - | Stock Option (Right to Buy) | |
| Guardant Health Inc | AmirAli Talasaz | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.18 per share. | 26 Jun 2026 | 143,028 | 2,024,364 (2%) | 0% | 4.2 | 597,857 | Common Stock |
| Trulieve Cannabis Corp | Kim A. Rivers | Director, Chairman and CEO, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 8.76 per share. | 26 Jun 2026 | 136,811 | 1,476,913 | - | 8.8 | 1,197,917 | Subordinate Voting Shares |
| Eos Energy Enterprises Inc (Class A) | Joe Mastrangelo | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 130,570 | 1,701,050 | - | 0 | Common Stock | |
| Eos Energy Enterprises Inc (Class A) | Joe Mastrangelo | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 130,570 | 261,140 | - | - | Restricted Stock Units | |
| Guardant Health Inc | AmirAli Talasaz | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 111,804 | 172,025 | - | - | Stock Option (Right to Buy) | |
| Guardant Health Inc | AmirAli Talasaz | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.18 per share. | 26 Jun 2026 | 111,804 | 1,998,308 (2%) | 0% | 4.2 | 467,341 | Common Stock |
| Mineralys Therapeutics Inc | Eric Warren | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 104,124 | 252,876 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | Eric Warren | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.90 per share. | 26 Jun 2026 | 104,124 | 38,400 | - | 25.9 | 2,696,322 | Common Stock |
| Mineralys Therapeutics Inc | Eric Warren | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.24 per share. | 26 Jun 2026 | 104,124 | 142,524 | - | 13.2 | 1,378,602 | Common Stock |
| Dyne Therapeutics Inc | Jason P. Rhodes | Director | Sale of securities on an exchange or to another person at price $ 21.14 per share. | 26 Jun 2026 | 102,969 | 4,476,487 | - | 21.1 | 2,176,765 | Common Stock |
| Personalis Inc | Christopher Hall | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 13.15 per share. | 26 Jun 2026 | 100,000 | 235,986 (0%) | 0% | 13.2 | 1,315,000 | Common Stock |
| Personalis Inc | Christopher Hall | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 100,000 | 200,000 | - | - | Stock Option (right to buy) | |
| Personalis Inc | Christopher Hall | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.61 per share. | 26 Jun 2026 | 100,000 | 335,986 (1%) | 0% | 1.6 | 161,000 | Common Stock |
| Affirm Holdings Inc (Class A) | Michael Linford | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.39 per share. | 26 Jun 2026 | 100,000 | 217,984 | - | 5.4 | 539,000 | Class A Common Stock |
| Affirm Holdings Inc (Class A) | Michael Linford | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 80.04 per share. | 26 Jun 2026 | 100,000 | 117,984 | - | 80.0 | 8,004,000 | Class A Common Stock |
| Affirm Holdings Inc (Class A) | Michael Linford | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 100,000 | 433,870 | - | - | Stock Option (Right to Buy) | |
| PaySign Inc | Joan M. Herman | Director, EVP, Operations | Sale of securities on an exchange or to another person at price $ 8.01 per share. | 26 Jun 2026 | 100,000 | 707,009 (1%) | 0% | 8.0 | 801,140 | Common Stock |
| Outset Medical Inc | Leslie L. Trigg | Director, Chair and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 99,160 | 198,034 | - | 0 | Common Stock | |
| Airbnb | Nathan Blecharczyk | Director, Chief Strategy Officer, Ten Percent Owner | 26 Jun 2026 | 96,263 | 108,633 | - | - | Class A Common Stock | ||
| Airbnb | Nathan Blecharczyk | Director, Chief Strategy Officer, Ten Percent Owner | 26 Jun 2026 | 96,263 | 45,770,277 | - | - | Class B Common Stock | ||
| Privia Health Group Inc | M. Shawn Morris | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.00 per share. | 26 Jun 2026 | 88,110 | 164,761 | - | 2 | 176,220 | Common Stock, par value $0.01 per share |
| Privia Health Group Inc | M. Shawn Morris | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 88,110 | 3,586,091 | - | - | Stock Option (Right to Purchase) | |
| Privia Health Group Inc | M. Shawn Morris | Director | Sale of securities on an exchange or to another person at price $ 25.33 per share. | 26 Jun 2026 | 88,110 | 76,651 | - | 25.3 | 2,231,826 | Common Stock, par value $0.01 per share |
| Dyne Therapeutics Inc | Jason P. Rhodes | Director | Sale of securities on an exchange or to another person at price $ 21.28 per share. | 26 Jun 2026 | 81,903 | 1,396,475 | - | 21.3 | 1,742,896 | Common Stock |
| Gaia Inc (Class A) | Ned Preston | CFO | Grant, award, or other acquisition of securities at price $ 2.08 per share. | 26 Jun 2026 | 76,220 | 90,444 (0%) | 0% | 2.1 | 158,538 | Class A Common Stock |
| Outset Medical Inc | Renee M. Gaeta | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 71,630 | 185,383 | - | 0 | Common Stock | |
| Guardant Health Inc | AmirAli Talasaz | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 151.47 per share. | 26 Jun 2026 | 70,513 | 1,928,039 (2%) | 0% | 151.5 | 10,680,315 | Common Stock |
| Fidelity National Fin Inc | Peter T. Sadowski | EVP, Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 45.70 per share. | 26 Jun 2026 | 69,196 | 5,702 (0%) | 0% | 45.7 | 3,162,375 | Common Stock |
| Mammoth Energy Services Inc | Phillip Lancaster | Director | Other type of transaction at price $ 0.00 per share. | 26 Jun 2026 | 68,152 | 159,445 (0%) | 0% | 0 | Common Stock | |
| Dyne Therapeutics Inc | Jason P. Rhodes | Director | Sale of securities on an exchange or to another person at price $ 21.28 per share. | 26 Jun 2026 | 64,411 | 1,016,633 | - | 21.3 | 1,370,666 | Common Stock |
| Guardant Health Inc | AmirAli Talasaz | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 150.49 per share. | 26 Jun 2026 | 64,037 | 1,934,271 (2%) | 0% | 150.5 | 9,636,838 | Common Stock |
| Privia Health Group Inc | M. Shawn Morris | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 63,212 | 3,522,879 | - | - | Stock Option (Right to Purchase) | |
| Privia Health Group Inc | M. Shawn Morris | Director | Sale of securities on an exchange or to another person at price $ 25.33 per share. | 26 Jun 2026 | 63,212 | 76,651 | - | 25.3 | 1,601,160 | Common Stock, par value $0.01 per share |
| Privia Health Group Inc | M. Shawn Morris | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.00 per share. | 26 Jun 2026 | 63,212 | 139,863 | - | 2 | 126,424 | Common Stock, par value $0.01 per share |
| Eos Energy Enterprises Inc (Class A) | Joe Mastrangelo | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.09 per share. | 26 Jun 2026 | 60,703 | 1,640,347 | - | 6.1 | 369,681 | Common Stock |
| Outset Medical Inc | John L. Brottem | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 59,830 | 90,107 | - | 0 | Common Stock | |
| Liberty Latin America Ltd (Class A) | John M. Winter | SVP, CLO AND SECRETARY | Other type of transaction at price $ 0.00 per share. | 26 Jun 2026 | 59,476 | 59,476 | - | 0 | Series A Preference Shares | |
| Lifeway Foods Inc | Edward P. Smolyansky | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 29.87 per share. | 26 Jun 2026 | 55,794 | 902,642 (5%) | 0% | 29.9 | 1,666,567 | Common Stock, no par value |
| Lifeway Foods Inc | Edward P. Smolyansky | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 28.64 per share. | 26 Jun 2026 | 55,754 | 958,436 (6%) | 0% | 28.6 | 1,596,795 | Common Stock, no par value |
| Guardant Health Inc | AmirAli Talasaz | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 151.16 per share. | 26 Jun 2026 | 52,935 | 1,881,336 (1%) | 0% | 151.2 | 8,001,628 | Common Stock |
| Dyne Therapeutics Inc | Jason P. Rhodes | Director | Sale of securities on an exchange or to another person at price $ 21.14 per share. | 26 Jun 2026 | 51,756 | 1,344,719 | - | 21.1 | 1,094,122 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.12 per share. | 26 Jun 2026 | 51,570 | 376,046 (0%) | 0% | 8.1 | 418,748 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 51,570 | 113,457 | - | - | Stock Option (right to buy) | |
| Personalis Inc | Aaron L. Tachibana | CFO AND COO | Sale of securities on an exchange or to another person at price $ 13.18 per share. | 26 Jun 2026 | 51,251 | 198,833 (0%) | 0% | 13.2 | 675,488 | Common Stock |
| ATAI Life Sciences N.V. | Gerd Kochendoerfer | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 5.00 per share. | 26 Jun 2026 | 50,000 | 0 | - | 5 | 250,000 | Common Stock |
| ATAI Life Sciences N.V. | Gerd Kochendoerfer | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 50,000 | 1,400,000 | - | - | Stock Option | |
| ATAI Life Sciences N.V. | Gerd Kochendoerfer | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.60 per share. | 26 Jun 2026 | 50,000 | 50,000 | - | 1.6 | 80,000 | Common Stock |
| Lifeway Foods Inc | Edward P. Smolyansky | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 29.56 per share. | 26 Jun 2026 | 50,000 | 852,642 (5%) | 0% | 29.6 | 1,478,000 | Common Stock, no par value |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 5.04 per share. | 26 Jun 2026 | 47,467 | 0 (0%) | 0% | 5.0 | 239,234 | Common Stock |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 47,467 | 0 | - | - | Stock Option (right to buy) | |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.50 per share. | 26 Jun 2026 | 47,467 | 47,467 (0%) | 0% | 2.5 | 118,668 | Common Stock |
| Guardant Health Inc | AmirAli Talasaz | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 152.20 per share. | 26 Jun 2026 | 46,663 | 1,881,376 (1%) | 0% | 152.2 | 7,102,319 | Common Stock |
| SEI Investments Co. | Alfred P. West | Chairman Emeritus | Sale of securities on an exchange or to another person at price $ 87.21 per share. | 26 Jun 2026 | 46,162 | 6,829,621 (4%) | 0% | 87.2 | 4,025,788 | Common Stock |
| Archer Aviation Inc (Class A) | Oscar Munoz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 40,983 | 40,983 | - | - | Restricted Stock Units | |
| Archer Aviation Inc (Class A) | Fred M. Diaz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 40,983 | 40,983 | - | - | Deferred Restricted Stock Units | |
| Archer Aviation Inc (Class A) | Deborah B. Diaz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 40,983 | 40,983 | - | - | Restricted Stock Units | |
| Archer Aviation Inc (Class A) | Maria Pinelli | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 40,983 | 40,983 | - | - | Restricted Stock Units | |
| Dyne Therapeutics Inc | Jason P. Rhodes | Director | Sale of securities on an exchange or to another person at price $ 21.14 per share. | 26 Jun 2026 | 40,702 | 975,931 | - | 21.1 | 860,440 | Common Stock |
| Black Diamond Therapeutics Inc | Kapil Dhingra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics Inc | Garry E. Menzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics Inc | Ali Behbahani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics Inc | Samarth Kulkarni | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics Inc | Prakash Raman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics Inc | Shannon Campbell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Worthington Steel Inc | Geoffrey G. Gilmore | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 39,915 | 344,932 | - | 0 | Common Shares | |
| Oportun Fin Corp | Richard N. Tambor | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jun 2026 | 36,127 | 40,650 (0%) | 0% | - | Common Stock | |
| Oportun Fin Corp | Richard N. Tambor | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jun 2026 | 36,127 | 36,127 (0%) | 0% | - | Common Stock | |
| Oportun Fin Corp | Richard N. Tambor | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jun 2026 | 36,127 | 4,523 (0%) | 0% | - | Common Stock | |
| Oportun Fin Corp | Richard N. Tambor | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Jun 2026 | 36,127 | 36,127 (0%) | 0% | - | Common Stock | |
| Immunovant Inc | Jay S. Stout | Chief Technology Officer | Sale of securities on an exchange or to another person at price $ 38.18 per share. | 26 Jun 2026 | 33,277 | 218,408 (0%) | 0% | 38.2 | 1,270,516 | Common Stock |
| Omada Health Inc | Steve Cook | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 19.89 per share. | 26 Jun 2026 | 33,000 | 133,359 | - | 19.9 | 656,449 | Common Stock |
| Omada Health Inc | Steve Cook | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 19.89 per share. | 26 Jun 2026 | 33,000 | 187,209 | - | 19.9 | 656,449 | Common Stock |
| Kymera Therapeutics Inc | Bruce Booth | Director | Sale of securities on an exchange or to another person at price $ 109.79 per share. | 26 Jun 2026 | 32,624 | 2,570,424 | - | 109.8 | 3,581,789 | Common Stock |
| Petmed Express Inc | Douglas Krulik | CAO and Interim CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 32,500 | 102,500 (0%) | 0% | 0 | Common Stock | |
| Petmed Express Inc | Douglas Krulik | CAO and Interim CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 32,500 | 32,500 | - | - | Performance Share Units | |
| Kymera Therapeutics Inc | Bruce Booth | Director | Sale of securities on an exchange or to another person at price $ 108.14 per share. | 26 Jun 2026 | 32,402 | 493,358 | - | 108.1 | 3,503,952 | Common Stock |
| Consumer Portfolio Service Inc | Charles E. Gonel | Sr. Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.53 per share. | 26 Jun 2026 | 30,000 | 54,847 (0%) | 0% | 3.5 | 105,900 | Common Stock, no par value |
| Consumer Portfolio Service Inc | Charles E. Gonel | Sr. Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 30,000 | 0 | - | - | Stock Option (right to buy) | |
| Eos Energy Enterprises Inc (Class A) | Michael W Silberman | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 29,996 | 313,275 | - | 0 | Common Stock | |
| Eos Energy Enterprises Inc (Class A) | Michael W Silberman | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 29,996 | 59,991 | - | - | Restricted Stock Units | |
| Erasca Inc | Alexander W. Casdin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 29,888 | 29,888 | - | - | Stock option (right to buy) | |
| Erasca Inc | Jean I. Liu | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 29,888 | 29,888 | - | - | Stock option (right to buy) | |
| Erasca Inc | Julie Hambleton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 29,888 | 29,888 | - | - | Stock option (right to buy) | |
| Erasca Inc | Pratik S. Multani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 29,888 | 29,888 | - | - | Stock option (right to buy) | |
| Erasca Inc | James A. Bristol | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 29,888 | 29,888 | - | - | Stock option (right to buy) | |
| Erasca Inc | Valerie Harding Start | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 29,888 | 29,888 | - | - | Stock option (right to buy) | |
| Personalis Inc | Aaron L. Tachibana | CFO AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.16 per share. | 26 Jun 2026 | 28,832 | 227,665 (0%) | 0% | 9.2 | 264,101 | Common Stock |
| Personalis Inc | Aaron L. Tachibana | CFO AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 28,832 | 0 | - | - | Stock Option (right to buy) | |
| Kymera Therapeutics Inc | Bruce Booth | Director | Sale of securities on an exchange or to another person at price $ 107.57 per share. | 26 Jun 2026 | 28,296 | 2,834,055 | - | 107.6 | 3,043,801 | Common Stock |
| Kymera Therapeutics Inc | Bruce Booth | Director | Sale of securities on an exchange or to another person at price $ 114.94 per share. | 26 Jun 2026 | 27,951 | 2,505,362 | - | 114.9 | 3,212,688 | Common Stock |
| Village Farms Intl Inc | Michael A. DeGiglio | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.89 per share. | 26 Jun 2026 | 26,400 | 9,682,175 (18%) | 0% | 1.9 | 49,896 | Common Shares |
| Ionis Pharma Inc | Eugene Schneider | EVP, Chf Clinical Develop Ofcr | Exercise or conversion of derivative security received from the company (such as an option) at price $ 60.89 per share. | 26 Jun 2026 | 26,000 | 103,114 (0%) | 0% | 60.9 | 1,583,140 | Common Stock |
| Ionis Pharma Inc | Eugene Schneider | EVP, Chf Clinical Develop Ofcr | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 26,000 | 26,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharma Inc | Eugene Schneider | EVP, Chf Clinical Develop Ofcr | Sale of securities on an exchange or to another person at price $ 81.05 per share. | 26 Jun 2026 | 26,000 | 77,114 (0%) | 0% | 81.0 | 2,107,196 | Common Stock |
| Guardant Health Inc | AmirAli Talasaz | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 150.53 per share. | 26 Jun 2026 | 25,812 | 1,998,552 (2%) | 0% | 150.5 | 3,885,434 | Common Stock |
| Stubhub Holdings Inc | Nayaab Islam | See Remarks | Sale of securities on an exchange or to another person at price $ 12.05 per share. | 26 Jun 2026 | 25,080 | 8,538,364 | - | 12.0 | 302,141 | Class A Common Stock |
| Alignment Healthcare Inc | Joseph Konowiecki | Director, EVP, Corporate Affairs | Sale of securities on an exchange or to another person at price $ 23.00 per share. | 26 Jun 2026 | 25,000 | 1,128,816 | - | 23 | 575,000 | Common Stock |
| American Healthcare REIT Inc | Brian S. Peay | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 50.70 per share. | 26 Jun 2026 | 25,000 | 152,700 | - | 50.7 | 1,267,403 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.46 per share. | 26 Jun 2026 | 24,944 | 299,532 (0%) | 0% | 8.5 | 211,026 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.99 per share. | 26 Jun 2026 | 24,944 | 324,476 (0%) | 0% | 4.0 | 99,527 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 24,944 | 37,416 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 24,944 | 87,303 | - | - | Stock Option (right to buy) | |
| IDT Corp (Class B) | Marcelo Fischer | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 56.98 per share. | 26 Jun 2026 | 23,323 | 32,824 (0%) | 0% | 57.0 | 1,329,024 | Class B Common Stock, $.01 par value per share |
| Eos Energy Enterprises Inc (Class A) | Michelle Buczkowski | Chief Administration Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 22,938 | 70,711 | - | 0 | Common Stock | |
| Eos Energy Enterprises Inc (Class A) | Michelle Buczkowski | Chief Administration Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 22,938 | 45,876 | - | - | Restricted Stock Units | |
| Canopy Growth Corp | David Lazzarato | Director | Sale of securities on an exchange or to another person at price $ 0.92 per share. | 26 Jun 2026 | 22,674 | 211,859 (0%) | 0% | 0.9 | 20,944 | Common Shares |
| Personalis Inc | Aaron L. Tachibana | CFO AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 22,419 | 7,471 | - | - | Stock Option (right to buy) | |
| Personalis Inc | Aaron L. Tachibana | CFO AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.32 per share. | 26 Jun 2026 | 22,419 | 250,084 (0%) | 0% | 5.3 | 119,269 | Common Stock |
| Galectin Therapeutics Inc | Harold H. Shlevin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 22,268 | 30,000 | - | - | Stock Option (right to buy) | |
| Galectin Therapeutics Inc | Harold H. Shlevin | Director | Sale of securities on an exchange or to another person at price $ 5.04 per share. | 26 Jun 2026 | 22,268 | 6,500 (0%) | 0% | 5.0 | 112,231 | Common Stock |
| Galectin Therapeutics Inc | Harold H. Shlevin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.23 per share. | 26 Jun 2026 | 22,268 | 28,768 (0%) | 0% | 1.2 | 27,390 | Common Stock |
| Kymera Therapeutics Inc | Bruce Booth | Director | Sale of securities on an exchange or to another person at price $ 117.85 per share. | 26 Jun 2026 | 22,046 | 2,464,314 | - | 117.8 | 2,598,121 | Common Stock |
| Gaia Inc (Class A) | Ned Preston | CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.08 per share. | 26 Jun 2026 | 21,417 | 69,027 (0%) | 0% | 2.1 | 44,547 | Class A Common Stock |
| Omada Health Inc | Steve Cook | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 19,427 | 20,834 | - | - | Stock Option (Right to Buy) | |
| Omada Health Inc | Steve Cook | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.01 per share. | 26 Jun 2026 | 19,427 | 220,209 | - | 8.0 | 155,610 | Common Stock |
| Kymera Therapeutics Inc | Bruce Booth | Director | Sale of securities on an exchange or to another person at price $ 107.76 per share. | 26 Jun 2026 | 19,419 | 2,412,158 | - | 107.8 | 2,092,591 | Common Stock |
| Lithium Americas Corp | Philip Montgomery | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 19,348 | 38,697 | - | - | Restricted Share Units ("RSUs") | |
| Lithium Americas Corp | Philip Montgomery | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 19,348 | 19,348 | - | - | Common Shares | |
| Orion Engineered Carbons S.A. | Dan F. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 19,150 | 110,857 (0%) | 0% | 0 | Common shares, no par value | |
| Orion Engineered Carbons S.A. | Yi Hyon Paik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 19,150 | 65,039 (0%) | 0% | 0 | Common shares, no par value | |
| Orion Engineered Carbons S.A. | Kerry A. Galvin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 19,150 | 84,753 (0%) | 0% | 0 | Common shares, no par value | |
| Orion Engineered Carbons S.A. | Paul E. Huck | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 19,150 | 103,357 (0%) | 0% | 0 | Common shares, no par value | |
| Orion Engineered Carbons S.A. | Didier Miraton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 19,150 | 73,357 (0%) | 0% | 0 | Common shares, no par value | |
| Orion Engineered Carbons S.A. | Mary A. Lindsey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 19,150 | 75,039 (0%) | 0% | 0 | Common shares, no par value | |
| Orion Engineered Carbons S.A. | Jacqueline Hoogerbrugge | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 19,150 | 32,085 (0%) | 0% | 0 | Common shares, no par value | |
| Archer Aviation Inc (Class A) | Oscar Munoz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 19,102 | 461,223 | - | 0 | Class A Common Stock | |
| Archer Aviation Inc (Class A) | Oscar Munoz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 19,102 | 0 | - | - | Restricted Stock Units | |
| Archer Aviation Inc (Class A) | Fred M. Diaz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 19,102 | 126,457 | - | 0 | Class A Common Stock | |
| Archer Aviation Inc (Class A) | Fred M. Diaz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 19,102 | 0 | - | - | Restricted Stock Units | |
| Archer Aviation Inc (Class A) | Deborah B. Diaz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 19,102 | 0 | - | - | Restricted Stock Units | |
| Archer Aviation Inc (Class A) | Deborah B. Diaz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 19,102 | 172,632 | - | 0 | Class A Common Stock | |
| Archer Aviation Inc (Class A) | Michael Spellacy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 19,102 | 0 | - | - | Restricted Stock Units | |
| Archer Aviation Inc (Class A) | Michael Spellacy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 19,102 | 73,746 | - | 0 | Class A Common Stock | |
| Archer Aviation Inc (Class A) | Maria Pinelli | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 19,102 | 0 | - | - | Restricted Stock Units | |
| Archer Aviation Inc (Class A) | Maria Pinelli | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 19,102 | 201,787 | - | 0 | Class A Common Stock | |
| Kymera Therapeutics Inc | Bruce Booth | Director | Sale of securities on an exchange or to another person at price $ 107.76 per share. | 26 Jun 2026 | 19,093 | 2,412,747 | - | 107.8 | 2,057,462 | Common Stock |
| Contineum Therapeutics Inc (Class A) | Troy A. Ignelzi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 19,000 | 19,000 | - | - | Stock Option (right to buy) | |
| Contineum Therapeutics Inc (Class A) | Sarah Boyce | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 19,000 | 19,000 | - | - | Stock Option (right to buy) | |
| Contineum Therapeutics Inc (Class A) | Olivia C. Ware | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 19,000 | 19,000 | - | - | Stock Option (right to buy) | |
| Contineum Therapeutics Inc (Class A) | Lori Lyons-Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 19,000 | 19,000 | - | - | Stock Option (right to buy) | |
| Contineum Therapeutics Inc (Class A) | Evert B. Schimmelpennink | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 19,000 | 19,000 | - | - | Stock Option (right to buy) | |
| Contineum Therapeutics Inc (Class A) | Diego Miralles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 19,000 | 19,000 | - | - | Stock Option (right to buy) | |
| Fulcrum Therapeutics Inc | Alan Ezekowitz | Director | Sale of securities on an exchange or to another person at price $ 3.65 per share. | 26 Jun 2026 | 18,000 | 10,927 (0%) | 0% | 3.6 | 65,614 | Common Stock |
| Omada Health Inc | Steve Cook | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.07 per share. | 26 Jun 2026 | 17,950 | 115,409 | - | 21.1 | 378,167 | Common Stock |
| Omada Health Inc | Steve Cook | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.28 per share. | 26 Jun 2026 | 17,950 | 205,159 | - | 8.3 | 148,626 | Common Stock |
| Omada Health Inc | Steve Cook | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.07 per share. | 26 Jun 2026 | 17,950 | 187,209 | - | 21.1 | 378,167 | Common Stock |
| Omada Health Inc | Steve Cook | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 17,950 | 301,809 | - | - | Stock Option (Right to Buy) | |
| Immunovant Inc | Christopher A. Van Tuyl | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 17,824 | 53,707 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | Christopher A. Van Tuyl | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.20 per share. | 26 Jun 2026 | 17,824 | 198,421 (0%) | 0% | 15.2 | 270,925 | Common Stock |
| Cathay General Bancorp | Chang M. Liu | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 17,727 | 17,727 | - | - | Restricted Stock Units | |
| Eos Energy Enterprises Inc (Class A) | Sumeet Puri | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 17,645 | 181,935 | - | 0 | Common Stock | |
| Eos Energy Enterprises Inc (Class A) | Sumeet Puri | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 17,545 | 35,389 | - | - | Restricted Stock Units | |
| Privia Health Group Inc | David Mountcastle | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 25.18 per share. | 26 Jun 2026 | 17,196 | 211,462 | - | 25.2 | 432,995 | Common Stock, par value $0.01 per share |
| Privia Health Group Inc | David Mountcastle | EVP & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.00 per share. | 26 Jun 2026 | 17,196 | 228,658 | - | 2 | 34,392 | Common Stock, par value $0.01 per share |
| Canopy Growth Corp | Theresa Yanofsky | Director | Sale of securities on an exchange or to another person at price $ 0.92 per share. | 26 Jun 2026 | 15,054 | 146,415 (0%) | 0% | 0.9 | 13,905 | Common Shares |
| Vericel Corp | Sean C. Flynn | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 45.64 per share. | 26 Jun 2026 | 15,000 | 1,647 (0%) | 0% | 45.6 | 684,600 | Common Stock |
| Vericel Corp | Sean C. Flynn | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 15,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| Vericel Corp | Sean C. Flynn | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.25 per share. | 26 Jun 2026 | 15,000 | 16,647 (0%) | 0% | 16.3 | 243,750 | Common Stock |
| Septerna Inc | Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Septerna Inc | Alan Ezekowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Septerna Inc | Bernard Coulie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Septerna Inc | Jake Simson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Septerna Inc | Abraham Bassan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Eos Energy Enterprises Inc (Class A) | Michael W Silberman | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 5.87 per share. | 26 Jun 2026 | 14,998 | 298,277 | - | 5.9 | 88,038 | Common Stock |
| Immunovant Inc | Christopher A. Van Tuyl | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 38.19 per share. | 26 Jun 2026 | 14,982 | 183,439 (0%) | 0% | 38.2 | 572,163 | Common Stock |
| Kymera Therapeutics Inc | Bruce Booth | Director | Sale of securities on an exchange or to another person at price $ 113.97 per share. | 26 Jun 2026 | 14,913 | 2,533,313 | - | 114.0 | 1,699,635 | Common Stock |
| Kymera Therapeutics Inc | Bruce Booth | Director | Sale of securities on an exchange or to another person at price $ 106.63 per share. | 26 Jun 2026 | 14,798 | 2,431,577 | - | 106.6 | 1,577,911 | Common Stock |
| AIAI Holdings Corp Ordinary | Barbara Barton Weiszhaar | SVP/CAO | Sale of securities on an exchange or to another person at price $ 14.21 per share. | 26 Jun 2026 | 14,781 | 161,339 | - | 14.2 | 210,038 | Class A Common Stock |
| AIAI Holdings Corp Ordinary | Stephanie Liebman | EVP/CFO | Sale of securities on an exchange or to another person at price $ 14.21 per share. | 26 Jun 2026 | 14,780 | 161,259 | - | 14.2 | 210,024 | Class A Common Stock |
| Immunovant Inc | Melanie Gloria | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 38.18 per share. | 26 Jun 2026 | 14,748 | 227,359 (0%) | 0% | 38.2 | 563,079 | Common Stock |
| Worthington Steel Inc | John B. Blystone | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 14,665 | 241,029 | - | 0 | Common Shares | |
| Kymera Therapeutics Inc | Bruce Booth | Director | Sale of securities on an exchange or to another person at price $ 106.63 per share. | 26 Jun 2026 | 14,613 | 2,431,840 | - | 106.6 | 1,558,184 | Common Stock |
| Intapp Inc | Michele Murgel | Chief People & Places Officer | Sale of securities on an exchange or to another person at price $ 25.02 per share. | 26 Jun 2026 | 14,591 | 233,632 | - | 25.0 | 365,127 | Common Stock |
| Lifeway Foods Inc | Edward P. Smolyansky | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 30.12 per share. | 26 Jun 2026 | 14,542 | 1,168,791 (7%) | 0% | 30.1 | 438,005 | Common Stock, no par value |
| Vicor Corp | Patrizio Vinciarelli | Director, Chairman & CEO, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 326.93 per share. | 26 Jun 2026 | 14,400 | 8,428,090 (29%) | 0% | 326.9 | 4,707,792 | Common Stock |
| Wheeler Real Estate Investment Trust Inc | Joseph D. Stilwell | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 26 Jun 2026 | 13,895 | 90,565 | - | - | Series B Convertible Preferred Stock | |
| La-Z-Boy Inc | Raphaell Z. Richmond | VP, GC & Chief Compliance Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.41 per share. | 26 Jun 2026 | 13,671 | 65,366 (0%) | 0% | 24.4 | 333,709 | Common Shares |
| La-Z-Boy Inc | Raphaell Z. Richmond | VP, GC & Chief Compliance Off | Sale of securities on an exchange or to another person at price $ 39.83 per share. | 26 Jun 2026 | 13,671 | 51,695 (0%) | 0% | 39.8 | 544,534 | Common Shares |
| La-Z-Boy Inc | Raphaell Z. Richmond | VP, GC & Chief Compliance Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 13,671 | 0 | - | - | Employee Stock Options (right to buy) | |
| Village Farms Intl Inc | Michael A. DeGiglio | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.87 per share. | 26 Jun 2026 | 13,600 | 9,695,775 (18%) | 0% | 1.9 | 25,432 | Common Shares |
| Omada Health Inc | Steve Cook | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 13,573 | 319,759 | - | - | Stock Option (Right to Buy) | |
| Omada Health Inc | Steve Cook | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.28 per share. | 26 Jun 2026 | 13,573 | 200,782 | - | 8.3 | 112,384 | Common Stock |
| Airbnb | Nathan Blecharczyk | Director, Chief Strategy Officer, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 146.59 per share. | 26 Jun 2026 | 13,041 | 86,390 | - | 146.6 | 1,911,736 | Class A Common Stock |
| Kymera Therapeutics Inc | Bruce Booth | Director | Sale of securities on an exchange or to another person at price $ 118.66 per share. | 26 Jun 2026 | 12,390 | 2,451,924 | - | 118.7 | 1,470,197 | Common Stock |
| Roivant Sciences Ltd | Keith Manchester | Director | Sale of securities on an exchange or to another person at price $ 35.28 per share. | 26 Jun 2026 | 12,380 | 13,689,166 | - | 35.3 | 436,766 | Common Shares |
| Roivant Sciences Ltd | Daniel Gold | Director | Sale of securities on an exchange or to another person at price $ 35.28 per share. | 26 Jun 2026 | 12,380 | 13,689,166 | - | 35.3 | 436,766 | Common Shares |
| Nexstar Media Grp Inc | Perry A. Sook | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 162.26 per share. | 26 Jun 2026 | 12,235 | 899,044 (1%) | 0% | 162.3 | 1,985,309 | Common Stock |
| Kymera Therapeutics Inc | Bruce Booth | Director | Sale of securities on an exchange or to another person at price $ 117.09 per share. | 26 Jun 2026 | 12,181 | 2,486,360 | - | 117.1 | 1,426,273 | Common Stock |
| C.H. Robinson Worldwide | David P. Bozeman | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 180.34 per share. | 26 Jun 2026 | 11,693 | 178,978 (0%) | 0% | 180.3 | 2,108,716 | Common Stock |
| Eos Energy Enterprises Inc (Class A) | Michelle Buczkowski | Chief Administration Officer | Sale of securities on an exchange or to another person at price $ 5.87 per share. | 26 Jun 2026 | 11,469 | 59,242 | - | 5.9 | 67,323 | Common Stock |
| Acadia Pharma Inc | James K. Kihara | PRINCIPAL ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 26.08 per share. | 26 Jun 2026 | 11,421 | 13,088 (0%) | 0% | 26.1 | 297,912 | Common Stock |
| Kymera Therapeutics Inc | Bruce Booth | Director | Sale of securities on an exchange or to another person at price $ 110.49 per share. | 26 Jun 2026 | 11,277 | 2,559,147 | - | 110.5 | 1,245,996 | Common Stock |
| Septerna Inc | Keith Gottesdiener | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 11,260 | 11,260 | - | - | Stock Option (Right to Buy) | |
| Wheeler Real Estate Investment Trust Inc | Joseph D. Stilwell | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 26 Jun 2026 | 11,105 | 72,383 | - | - | Series B Convertible Preferred Stock | |
| Consumer Portfolio Service Inc | Charles E. Gonel | Sr. Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.00 per share. | 26 Jun 2026 | 11,095 | 43,752 (0%) | 0% | 10 | 110,950 | Common Stock, no par value |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.14 per share. | 26 Jun 2026 | 11,034 | 283,785 (0%) | 0% | 12.1 | 133,953 | Common Stock |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 11,034 | 1,837 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Sharon Benzeno | Chief Commercial Ofc Imm Med | Sale of securities on an exchange or to another person at price $ 21.00 per share. | 26 Jun 2026 | 11,034 | 272,751 (0%) | 0% | 21 | 231,714 | Common Stock |
| Kymera Therapeutics Inc | Bruce Booth | Director | Sale of securities on an exchange or to another person at price $ 108.28 per share. | 26 Jun 2026 | 10,848 | 2,401,310 | - | 108.3 | 1,174,621 | Common Stock |
| Kymera Therapeutics Inc | Bruce Booth | Director | Sale of securities on an exchange or to another person at price $ 108.28 per share. | 26 Jun 2026 | 10,658 | 2,402,089 | - | 108.3 | 1,154,048 | Common Stock |
| Worthington Steel Inc | Jeffrey R. Klingler | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 10,590 | 103,802 | - | 0 | Common Shares | |
| Kymera Therapeutics Inc | Bruce Booth | Director | Sale of securities on an exchange or to another person at price $ 111.51 per share. | 26 Jun 2026 | 10,366 | 2,548,781 | - | 111.5 | 1,155,913 | Common Stock |
| Paychex | Joseph M. Tucci | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 60.59 per share. | 26 Jun 2026 | 10,220 | 77,584 (0%) | 0% | 60.6 | 619,230 | Common Stock |
| Paychex | Joseph M. Tucci | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 10,220 | 0 | - | - | Stock Option | |
| Atlanticus Holdings Corp | William R. McCamey | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 109.45 per share. | 26 Jun 2026 | 10,000 | 137,410 (0%) | 0% | 109.5 | 1,094,500 | Common Stock |
| Atlanticus Holdings Corp | Jeffrey A. Howard | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 109.45 per share. | 26 Jun 2026 | 10,000 | 673,265 (4%) | 0% | 109.5 | 1,094,500 | Common Stock |
| Immunovant Inc | Tiago M. Girao | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.90 per share. | 26 Jun 2026 | 10,000 | 257,596 (0%) | 0% | 15.9 | 159,000 | Common Stock |
| Immunovant Inc | Tiago M. Girao | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 10,000 | 283,505 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | Tiago M. Girao | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 38.46 per share. | 26 Jun 2026 | 10,000 | 247,596 (0%) | 0% | 38.5 | 384,600 | Common Stock |
| Phio Pharma Corp | Robert J. Bitterman | Director, Chairman, Pres. & CEO | Purchase of securities on an exchange or from another person at price $ 0.99 per share. | 26 Jun 2026 | 10,000 | 421,421 (22%) | 0% | 1.0 | 9,900 | Common Stock, $.0001 par value |
| Eton Pharma Inc | David C. Krempa | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 10,000 | 96,829 | - | - | Restricted Stock Units | |
| Qualys Inc | Sumedh S. Thakar | Director, CEO & PRESIDENT | Sale of securities on an exchange or to another person at price $ 120.47 per share. | 26 Jun 2026 | 9,800 | 236,886 (0%) | 0% | 120.5 | 1,180,594 | Common Stock |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 135.42 per share. | 26 Jun 2026 | 9,500 | 50,013 (0%) | 0% | 135.4 | 1,286,490 | Common Stock |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 9,500 | 106,218 | - | - | Stock Option | |
| Cathay General Bancorp | Chang M. Liu | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 9,408 | 9,408 | - | - | Restricted Stock Units | |
| Ultra Clean Hldgs Inc | Brian E. Harding | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 9,363 | 37,418 (0%) | 0% | 0 | Common Stock | |
| Airbnb | Nathan Blecharczyk | Director, Chief Strategy Officer, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 145.58 per share. | 26 Jun 2026 | 9,202 | 99,431 | - | 145.6 | 1,339,623 | Class A Common Stock |
| Cathay General Bancorp | Dunson K. Cheng | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 9,186 | 9,186 | - | - | Restricted Stock Units | |
| Vaxcyte Inc | Grant E. Pickering | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 55.26 per share. | 26 Jun 2026 | 9,137 | 458,883 | - | 55.3 | 504,956 | Common Stock |
| Privia Health Group Inc | David Mountcastle | EVP & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 8,897 | 0 | - | - | Stock Option (Right to Purchase) | |
| Cathay General Bancorp | Chang M. Liu | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 8,863 | 8,863 | - | - | Restricted Stock Units | |
| Eos Energy Enterprises Inc (Class A) | Sumeet Puri | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 5.86 per share. | 26 Jun 2026 | 8,823 | 173,112 | - | 5.9 | 51,703 | Common Stock |
| Airbnb | Nathan Blecharczyk | Director, Chief Strategy Officer, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 147.07 per share. | 26 Jun 2026 | 8,790 | 77,600 | - | 147.1 | 1,292,773 | Class A Common Stock |
| Worthington Steel Inc | Timothy A. Adams | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 8,150 | 52,248 | - | 0 | Common Shares | |
| Neurocrine Biosciences Inc | Darin M. Lippoldt | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 8,110 | 16,655 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences Inc | Darin M. Lippoldt | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 81.49 per share. | 26 Jun 2026 | 8,110 | 62,839 (0%) | 0% | 81.5 | 660,884 | Common Stock |
| Neurocrine Biosciences Inc | Darin M. Lippoldt | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 170.03 per share. | 26 Jun 2026 | 8,110 | 54,729 (0%) | 0% | 170.0 | 1,378,903 | Common Stock |
| Kymera Therapeutics Inc | Bruce Booth | Director | Sale of securities on an exchange or to another person at price $ 109.75 per share. | 26 Jun 2026 | 7,968 | 2,393,342 | - | 109.8 | 874,488 | Common Stock |
| Kymera Therapeutics Inc | Bruce Booth | Director | Sale of securities on an exchange or to another person at price $ 109.75 per share. | 26 Jun 2026 | 7,833 | 2,394,256 | - | 109.8 | 859,672 | Common Stock |
| Galectin Therapeutics Inc | Harold H. Shlevin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.23 per share. | 26 Jun 2026 | 7,732 | 14,232 (0%) | 0% | 1.2 | 9,510 | Common Stock |
| Galectin Therapeutics Inc | Harold H. Shlevin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 7,732 | 52,268 | - | - | Stock Option (right to buy) | |
| Galectin Therapeutics Inc | Harold H. Shlevin | Director | Sale of securities on an exchange or to another person at price $ 5.00 per share. | 26 Jun 2026 | 7,732 | 6,500 (0%) | 0% | 5 | 38,660 | Common Stock |
| Kymera Therapeutics Inc | Bruce Booth | Director | Sale of securities on an exchange or to another person at price $ 110.67 per share. | 26 Jun 2026 | 7,723 | 2,385,619 | - | 110.7 | 854,704 | Common Stock |
| PTC Therapeutics Inc | Neil Almstead | CHIEF TECHNICAL OPS OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 7,718 | 19,687 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Neil Almstead | CHIEF TECHNICAL OPS OFFICER | Sale of securities on an exchange or to another person at price $ 85.26 per share. | 26 Jun 2026 | 7,718 | 60,137 (0%) | 0% | 85.3 | 658,037 | Common Stock |
| PTC Therapeutics Inc | Neil Almstead | CHIEF TECHNICAL OPS OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.10 per share. | 26 Jun 2026 | 7,718 | 67,855 (0%) | 0% | 38.1 | 294,056 | Common Stock |
| Kymera Therapeutics Inc | Bruce Booth | Director | Sale of securities on an exchange or to another person at price $ 110.67 per share. | 26 Jun 2026 | 7,602 | 2,386,654 | - | 110.7 | 841,313 | Common Stock |
| Worthington Steel Inc | John B. Blystone | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.16 per share. | 26 Jun 2026 | 7,414 | 233,615 | - | 35.2 | 260,676 | Common Shares |
| Redwood Trust Inc | Debora D. Horvath | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 7,259 | 0 | - | - | Deferred Stock Units | |
| Redwood Trust Inc | Debora D. Horvath | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.73 per share. | 26 Jun 2026 | 7,259 | 156,295 (0%) | 0% | 4.7 | 34,335 | Common stock |
| Westwood Holdings Grp Inc | Susan M. Byrne | Director Emerita | Sale of securities on an exchange or to another person at price $ 20.03 per share. | 26 Jun 2026 | 7,192 | 240,000 (2%) | 0% | 20.0 | 144,045 | common stock |
| Westwood Holdings Grp Inc | Susan M. Byrne | Director Emerita | Sale of securities on an exchange or to another person at price $ 20.03 per share. | 26 Jun 2026 | 7,129 | 240,108 (2%) | 0% | 20.0 | 142,783 | common stock |
| First US Bancshares Inc | Thomas S. Elley | SEVP,CFO,Trea,Ast Sec-FUSB | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.11 per share. | 26 Jun 2026 | 7,000 | 43,000 (0%) | 0% | 14.1 | 98,770 | Common Stock, $.01 par value |
| First US Bancshares Inc | Thomas S. Elley | SEVP,CFO,Trea,Ast Sec-FUSB | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 7,000 | 0 | - | - | Stock Option (right to buy) | |
| Kymera Therapeutics Inc | Bruce Booth | Director | Sale of securities on an exchange or to another person at price $ 115.69 per share. | 26 Jun 2026 | 6,821 | 2,498,541 | - | 115.7 | 789,121 | Common Stock |
| Immunovant Inc | Jay S. Stout | Chief Technology Officer | Sale of securities on an exchange or to another person at price $ 38.94 per share. | 26 Jun 2026 | 6,723 | 211,685 (0%) | 0% | 38.9 | 261,794 | Common Stock |
| Vaxcyte Inc | Grant E. Pickering | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 54.28 per share. | 26 Jun 2026 | 6,683 | 468,020 | - | 54.3 | 362,720 | Common Stock |
| Blackstone Mortgage Trust Inc (Class A) | Henry N. Nassau | Director | Grant, award, or other acquisition of securities at price $ 17.43 per share. | 26 Jun 2026 | 6,597 | 205,479 (0%) | 0% | 17.4 | 114,986 | Class A Common Stock |
| Blackstone Mortgage Trust Inc (Class A) | Leonard W. Cotton | Director | Grant, award, or other acquisition of securities at price $ 17.43 per share. | 26 Jun 2026 | 6,597 | 96,890 (0%) | 0% | 17.4 | 114,986 | Class A Common Stock |
| Blackstone Mortgage Trust Inc (Class A) | Lynne B. Sagalyn | Director | Grant, award, or other acquisition of securities at price $ 17.43 per share. | 26 Jun 2026 | 6,597 | 162,700 (0%) | 0% | 17.4 | 114,986 | Class A Common Stock |
| Blackstone Mortgage Trust Inc (Class A) | Michael B. Nash | Director | Grant, award, or other acquisition of securities at price $ 17.43 per share. | 26 Jun 2026 | 6,597 | 558,272 (0%) | 0% | 17.4 | 114,986 | Class A Common Stock |
| Blackstone Mortgage Trust Inc (Class A) | Nnenna J. Lynch | Director | Grant, award, or other acquisition of securities at price $ 17.43 per share. | 26 Jun 2026 | 6,597 | 41,805 (0%) | 0% | 17.4 | 114,986 | Class A Common Stock |
| Blackstone Mortgage Trust Inc (Class A) | Gilda Perez-Alvarado | Director | Grant, award, or other acquisition of securities at price $ 17.43 per share. | 26 Jun 2026 | 6,597 | 26,504 (0%) | 0% | 17.4 | 114,986 | Class A Common Stock |
| Blackstone Mortgage Trust Inc (Class A) | Chen Yi Hsu | Director | Grant, award, or other acquisition of securities at price $ 17.43 per share. | 26 Jun 2026 | 6,597 | 10,850 (0%) | 0% | 17.4 | 114,986 | Class A Common Stock |
| Vaxcyte Inc | Grant E. Pickering | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 56.12 per share. | 26 Jun 2026 | 6,417 | 452,466 | - | 56.1 | 360,128 | Common Stock |
| La-Z-Boy Inc | Melinda D. Whittington | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 40.95 per share. | 26 Jun 2026 | 6,376 | 397,365 (0%) | 0% | 40.9 | 261,097 | Common Shares |
| Paychex | Joseph M. Tucci | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 98.10 per share. | 26 Jun 2026 | 6,313 | 71,271 (0%) | 0% | 98.1 | 619,305 | Common Stock |
| Amarin Corp (ADR) | Aaron D. Berg | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 6,250 | 6,250 | - | - | Restricted Stock Unit | |
| Amarin Corp (ADR) | Aaron D. Berg | President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 6,250 | 88,845 (0%) | 0% | - | American Depositary Shares | |
| First US Bancshares Inc | Thomas S. Elley | SEVP,CFO,Trea,Ast Sec-FUSB | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.75 per share. | 26 Jun 2026 | 6,220 | 36,780 (0%) | 0% | 16.8 | 104,185 | Common Stock, $.01 par value |
| Worthington Steel Inc | Clifford Larivey | President Flat Rolled Stl Proc | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 6,110 | 70,418 | - | 0 | Common Shares | |
| vTv Therapeutics Inc (Class A) | Daniel K. Spiegelman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 6,000 | 16,000 | - | - | Director stock option (right to buy) | |
| vTv Therapeutics Inc (Class A) | Anne M. Phillips | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 6,000 | 16,860 | - | - | Director stock option (right to buy) | |
| vTv Therapeutics Inc (Class A) | Fahed Al Marzooqi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 6,000 | 19,555 | - | - | Director stock option (right to buy) | |
| Privia Health Group Inc | David Mountcastle | EVP & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 5,962 | 0 | - | - | Stock Option (Right to Purchase) | |
| SEI Investments Co. | Alfred P. West | Chairman Emeritus | Sale of securities on an exchange or to another person at price $ 87.18 per share. | 26 Jun 2026 | 5,652 | 6,820,131 (4%) | 0% | 87.2 | 492,741 | Common Stock |
| Cathay General Bancorp | Albert Jen-Wen Wang | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 5,640 | 5,640 | - | - | Restricted Stock Units | |
| Kymera Therapeutics Inc | Bruce Booth | Director | Sale of securities on an exchange or to another person at price $ 105.78 per share. | 26 Jun 2026 | 5,549 | 2,446,375 | - | 105.8 | 586,973 | Common Stock |
| Kymera Therapeutics Inc | Bruce Booth | Director | Sale of securities on an exchange or to another person at price $ 105.78 per share. | 26 Jun 2026 | 5,471 | 2,446,453 | - | 105.8 | 578,722 | Common Stock |
| Agenus Inc | Garo H. Armen | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 3.03 per share. | 26 Jun 2026 | 5,364 | 366,256 (0%) | 0% | 3.0 | 16,253 | Common Stock |
| Asana Inc (Class A) | Katie Colendich | GC, Corporate Secretary | Sale of securities on an exchange or to another person at price $ 6.69 per share. | 26 Jun 2026 | 5,242 | 176,598 | - | 6.7 | 35,043 | Class A Common Stock |
| Micron Tech | Sanjay Mehrotra | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 1132.37 per share. | 26 Jun 2026 | 5,123 | 378,902 (0%) | 0% | 1132.4 | 5,801,132 | Common Stock |
| Beta Bionics Inc | Stephen Feider | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 17.05 per share. | 26 Jun 2026 | 5,104 | 165,931 | - | 17.0 | 87,006 | Common Stock |
| Beta Bionics Inc | Stephen Feider | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.10 per share. | 26 Jun 2026 | 5,104 | 171,157 | - | 5.1 | 26,030 | Common Stock |
| Beta Bionics Inc | Stephen Feider | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 5,104 | 44,591 | - | - | Employee Stock Option (right to buy) | |
| Beta Bionics Inc | Stephen Feider | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 17.05 per share. | 26 Jun 2026 | 5,104 | 166,053 | - | 17.0 | 87,006 | Common Stock |
| Liberty Latin America Ltd (Class A) | John M. Winter | SVP, CLO AND SECRETARY | Purchase of securities on an exchange or from another person at price $ 19.67 per share. | 26 Jun 2026 | 5,071 | 64,547 | - | 19.7 | 99,738 | Series A Preference Shares |
| Silvergate Cap Corp (Class A) | Paul R. Buckman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 5,046 | 63,750 | - | 0 | Common Stock | |
| Silvergate Cap Corp (Class A) | Kevin K. Sidow | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 5,046 | 25,056 | - | 0 | Common Stock | |
| Silvergate Cap Corp (Class A) | Casey M. Tansey | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 5,046 | 52,712 | - | 0 | Common Stock | |
| Silvergate Cap Corp (Class A) | Richard J. Buchholz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 5,046 | 18,712 | - | 0 | Common Stock | |
| Silvergate Cap Corp (Class A) | Andrew Hykes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 5,046 | 6,769 | - | 0 | Common Stock | |
| Vericel Corp | Jonathan Mark Hopper | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 5,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Vericel Corp | Jonathan Mark Hopper | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 29.82 per share. | 26 Jun 2026 | 5,000 | 80,753 (0%) | 0% | 29.8 | 149,100 | Common Stock |
| Vericel Corp | Jonathan Mark Hopper | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 26 Jun 2026 | 5,000 | 75,753 (0%) | 0% | 45 | 225,000 | Common Stock |
| Vericel Corp | Jonathan Mark Hopper | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 29.82 per share. | 26 Jun 2026 | 5,000 | 80,753 (0%) | 0% | 29.8 | 149,100 | Common Stock |
| Vericel Corp | Jonathan Mark Hopper | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 26 Jun 2026 | 5,000 | 75,753 (0%) | 0% | 45 | 225,000 | Common Stock |
| Vericel Corp | Jonathan Mark Hopper | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 5,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Vericel Corp | Joseph A. Mara | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 44.75 per share. | 26 Jun 2026 | 5,000 | 16,009 (0%) | 0% | 44.8 | 223,750 | Common Stock |
| AIAI Holdings Corp Ordinary | Barbara Barton Weiszhaar | SVP/CAO | Sale of securities on an exchange or to another person at price $ 15.21 per share. | 26 Jun 2026 | 5,000 | 176,120 | - | 15.2 | 76,050 | Class A Common Stock |
| AIAI Holdings Corp Ordinary | Stephanie Liebman | EVP/CFO | Sale of securities on an exchange or to another person at price $ 14.75 per share. | 26 Jun 2026 | 5,000 | 176,039 | - | 14.8 | 73,750 | Class A Common Stock |
| AIAI Holdings Corp Ordinary | Stephanie Liebman | EVP/CFO | Sale of securities on an exchange or to another person at price $ 15.21 per share. | 26 Jun 2026 | 5,000 | 181,039 | - | 15.2 | 76,050 | Class A Common Stock |
| Beta Bionics Inc | Stephen Feider | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.10 per share. | 26 Jun 2026 | 4,982 | 171,035 | - | 5.1 | 25,408 | Common Stock |
| Beta Bionics Inc | Stephen Feider | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 4,982 | 44,713 | - | - | Employee Stock Option (right to buy) | |
| Beta Bionics Inc | Stephen Feider | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 4,896 | 39,817 | - | - | Employee Stock Option (right to buy) | |
| Beta Bionics Inc | Stephen Feider | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 17.03 per share. | 26 Jun 2026 | 4,896 | 165,931 | - | 17.0 | 83,381 | Common Stock |
| Beta Bionics Inc | Stephen Feider | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.10 per share. | 26 Jun 2026 | 4,896 | 170,827 | - | 5.1 | 24,970 | Common Stock |
| Beta Bionics Inc | Stephen Feider | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 4,896 | 39,695 | - | - | Employee Stock Option (right to buy) | |
| Beta Bionics Inc | Stephen Feider | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 17.03 per share. | 26 Jun 2026 | 4,896 | 166,053 | - | 17.0 | 83,381 | Common Stock |
| Beta Bionics Inc | Stephen Feider | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.10 per share. | 26 Jun 2026 | 4,896 | 170,949 | - | 5.1 | 24,970 | Common Stock |
| Worthington Steel Inc | Joseph Y Heuer | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 4,890 | 19,169 | - | 0 | Common Shares | |
| Cathay General Bancorp | Dunson K. Cheng | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 4,875 | 4,875 | - | - | Restricted Stock Units | |
| Genesco Inc | Mimi Eckel Vaughn | Director, Board Chair, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 36.18 per share. | 26 Jun 2026 | 4,847 | 445,481 (3%) | 0% | 36.2 | 175,364 | Common Stock |
| Modiv Inc (Class C) | Aaron Scott Halfacre | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 17.50 per share. | 26 Jun 2026 | 4,766 | 133,244 | - | 17.5 | 83,409 | COMMON STOCK, CLASS C |
| Cathay General Bancorp | Dunson K. Cheng | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 4,593 | 4,593 | - | - | Restricted Stock Units | |
| Kymera Therapeutics Inc | Bruce Booth | Director | Sale of securities on an exchange or to another person at price $ 109.79 per share. | 26 Jun 2026 | 4,562 | 488,796 | - | 109.8 | 500,862 | Common Stock |
| J.M. Smucker | Jeannette L. Knudsen | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 115.08 per share. | 26 Jun 2026 | 4,353 | 16,835 (0%) | 0% | 115.1 | 500,943 | Common Shares |
| VF Corp | Richard T. Carucci | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 4,317 | 100,113 | - | - | Phantom Stock-d | |
| Westwood Holdings Grp Inc | Susan M. Byrne | Director Emerita | Sale of securities on an exchange or to another person at price $ 19.39 per share. | 26 Jun 2026 | 4,274 | 247,237 (2%) | 0% | 19.4 | 82,856 | common stock |
| Westwood Holdings Grp Inc | Susan M. Byrne | Director Emerita | Sale of securities on an exchange or to another person at price $ 19.39 per share. | 26 Jun 2026 | 4,274 | 247,192 (2%) | 0% | 19.4 | 82,856 | common stock |
| Kymera Therapeutics Inc | Bruce Booth | Director | Sale of securities on an exchange or to another person at price $ 107.57 per share. | 26 Jun 2026 | 3,958 | 525,760 | - | 107.6 | 425,762 | Common Stock |
| Paychex | Joseph M. Tucci | Director | Sale of securities on an exchange or to another person at price $ 98.25 per share. | 26 Jun 2026 | 3,907 | 67,364 (0%) | 0% | 98.3 | 383,863 | Common Stock |
| Kymera Therapeutics Inc | Bruce Booth | Director | Sale of securities on an exchange or to another person at price $ 114.94 per share. | 26 Jun 2026 | 3,896 | 479,718 | - | 114.9 | 447,806 | Common Stock |
| SEI Investments Co. | Alfred P. West | Chairman Emeritus | Sale of securities on an exchange or to another person at price $ 87.67 per share. | 26 Jun 2026 | 3,838 | 6,825,783 (4%) | 0% | 87.7 | 336,477 | Common Stock |
| Terex Corp | David A. Sachs | Director | Grant, award, or other acquisition of securities at price $ 71.81 per share. | 26 Jun 2026 | 3,760 | 279,590 (0%) | 0% | 71.8 | 270,006 | Common Stock, par value $.01 |
| Terex Corp | Srikanth Padmanabhan | Director | Grant, award, or other acquisition of securities at price $ 71.81 per share. | 26 Jun 2026 | 3,760 | 6,641 (0%) | 0% | 71.8 | 270,006 | Common Stock, $ .01 par value |
| Terex Corp | Sandra E. O’Connor | Director | Grant, award, or other acquisition of securities at price $ 71.81 per share. | 26 Jun 2026 | 3,760 | 47,264 (0%) | 0% | 71.8 | 270,006 | Common Stock, $.01 par value |
| Terex Corp | Oluseun Salami | Director | Grant, award, or other acquisition of securities at price $ 71.81 per share. | 26 Jun 2026 | 3,760 | 16,740 (0%) | 0% | 71.8 | 270,006 | Common Stock, $ .01 par value |
| Terex Corp | Kathleen M. Steele | Director | Grant, award, or other acquisition of securities at price $ 71.81 per share. | 26 Jun 2026 | 3,760 | 16,287 (0%) | 0% | 71.8 | 270,006 | Common Stock, $ .01 par value |
| CarMax | David W. McCreight | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 3,696 | 39,530 (0%) | 0% | 0 | Common Stock | |
| CarMax | Sona Chawla | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 3,696 | 25,398 (0%) | 0% | 0 | Common Stock | |
| CarMax | Peter J. Bensen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 3,696 | 28,492 (0%) | 0% | 0 | Common Stock | |
| CarMax | Thomas J. Folliard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 3,696 | 227,754 (0%) | 0% | 0 | Common Stock | |
| CarMax | William C. Cobb | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 3,696 | 3,696 (0%) | 0% | 0 | Common Stock | |
| CarMax | Mark F. O'Neil | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 3,696 | 33,186 (0%) | 0% | 0 | Common Stock | |
| CarMax | Pietro Satriano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 3,696 | 20,011 (0%) | 0% | 0 | Common Stock | |
| CarMax | Marcella Shinder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 3,696 | 28,689 (0%) | 0% | 0 | Common Stock | |
| CarMax | James Francis Kessler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 3,696 | 3,696 (0%) | 0% | 0 | Common Stock | |
| Orchid Island Cap Inc | Robert E. Cauley | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 3,694 | 126,995 | - | - | Performance Units | |
| Orchid Island Cap Inc | Robert E. Cauley | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 3,694 | 226,984 (0%) | 0% | 0 | Common Stock | |
| Orasure Tech Inc | Steven Kyle Boyd | Director | Grant, award, or other acquisition of securities at price $ 4.43 per share. | 26 Jun 2026 | 3,666 | 163,234 (0%) | 0% | 4.4 | 16,250 | Common Stock |
| Micron Tech | Sanjay Mehrotra | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 1141.46 per share. | 26 Jun 2026 | 3,645 | 373,710 (0%) | 0% | 1141.5 | 4,160,622 | Common Stock |
| Signet Jewelers Ltd | Helen E. McCluskey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 3,632 | 39,381 (0%) | 0% | 0 | Common Shares, par value $0.18 | |
| Cathay General Bancorp | Diana G. Deen | EVP, Chief Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 3,400 | 3,400 | - | - | Restricted Stock Units | |
| La-Z-Boy Inc | Melinda D. Whittington | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 40.95 per share. | 26 Jun 2026 | 3,381 | 393,984 (0%) | 0% | 41.0 | 138,452 | Common Shares |
| CarGurus Inc (Class A) | Javier Esquivel Zamora | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 32.61 per share. | 26 Jun 2026 | 3,367 | 99,694 (0%) | 0% | 32.6 | 109,798 | Class A Common Stock |
| Credit Acceptance Corp | Erin J. Kerber | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 3,303 | 5,500 | - | - | Employee Stock Option (right to buy) | |
| Credit Acceptance Corp | Erin J. Kerber | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 454.11 per share. | 26 Jun 2026 | 3,303 | 31,430 (0%) | 0% | 454.1 | 1,499,925 | Common Stock |
| Liquidity Services Inc | John P. Daunt | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 3,287 | 15,413 | - | - | Stock Option Grant | |
| Liquidity Services Inc | John P. Daunt | EVP, Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.62 per share. | 26 Jun 2026 | 3,287 | 41,373 (0%) | 0% | 21.6 | 71,065 | Common Stock |
| Park-Ohio Holdings Corp | Robert D. Vilsack | Secretary & CLO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.06 per share. | 26 Jun 2026 | 3,266 | 192,943 (1%) | 0% | 39.1 | 127,570 | Common Stock |
| Canopy Growth Corp | Joe Bayern | Director | Sale of securities on an exchange or to another person at price $ 0.92 per share. | 26 Jun 2026 | 3,197 | 145,127 (0%) | 0% | 0.9 | 2,953 | Common Shares |
| Canopy Growth Corp | Margaret Shan Atkins | Director | Sale of securities on an exchange or to another person at price $ 0.92 per share. | 26 Jun 2026 | 3,197 | 146,517 (0%) | 0% | 0.9 | 2,953 | Common Shares |
| Amarin Corp (ADR) | Aaron D. Berg | President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.35 per share. | 26 Jun 2026 | 3,197 | 85,648 (0%) | 0% | 16.4 | 52,271 | American Depositary Shares |
| Cathay General Bancorp | Albert Jen-Wen Wang | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 3,134 | 3,134 | - | - | Restricted Stock Units | |
| Cathay General Bancorp | Albert Sun | EVP, Chief Credit Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 3,102 | 3,102 | - | - | Restricted Stock Units | |
| Park-Ohio Holdings Corp | Robert D. Vilsack | Secretary & CLO | Sale of securities on an exchange or to another person at price $ 38.40 per share. | 26 Jun 2026 | 3,100 | 188,471 (1%) | 0% | 38.4 | 119,040 | Common Stock |
| Ionis Pharma Inc | Patrick R. O'Neil | EVP CLO & General Counsel | Sale of securities on an exchange or to another person at price $ 80.00 per share. | 26 Jun 2026 | 3,069 | 61,470 (0%) | 0% | 80 | 245,520 | Common Stock |
| Kymera Therapeutics Inc | Bruce Booth | Director | Sale of securities on an exchange or to another person at price $ 117.85 per share. | 26 Jun 2026 | 3,069 | 473,996 | - | 117.9 | 361,682 | Common Stock |
| Orchid Island Cap Inc | George H. Haas | Director, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 3,031 | 97,939 | - | - | Performance Units | |
| Orchid Island Cap Inc | George H. Haas | Director, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2026 | 3,031 | 138,715 (0%) | 0% | 0 | Common Stock | |
| Kymera Therapeutics Inc | Bruce Booth | Director | Sale of securities on an exchange or to another person at price $ 107.76 per share. | 26 Jun 2026 | 3,024 | 466,077 | - | 107.8 | 325,866 | Common Stock |
| MediaAlpha Inc (Class A) | Amy Yeh | Chief Technology Officer | Sale of securities on an exchange or to another person at price $ 11.16 per share. | 26 Jun 2026 | 3,000 | 566,985 | - | 11.2 | 33,480 | Class A Common Stock |
| Immunovant Inc | Melanie Gloria | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 38.95 per share. | 26 Jun 2026 | 2,966 | 224,393 (0%) | 0% | 39.0 | 115,526 | Common Stock |
| Scynexis Inc | David C. Hastings | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 2,875 | 2,875 | - | - | Stock Option (Right to Buy) | |
| Scynexis Inc | David C. Hastings | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 2,875 | 11,522 (0%) | 0% | 0 | Common Stock | |
| Scynexis Inc | Guy Macdonald | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 2,875 | 2,875 | - | - | Stock Option (Right to Buy) | |
| Scynexis Inc | Guy Macdonald | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 2,875 | 12,625 (0%) | 0% | 0 | Common Stock | |
| Scynexis Inc | Armando Anido | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 2,875 | 11,750 (0%) | 0% | 0 | Common Stock | |
| Scynexis Inc | Armando Anido | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 2,875 | 2,875 | - | - | Stock Option (Right to Buy) | |
| Scynexis Inc | Ann F. Hanham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 2,875 | 11,577 (0%) | 0% | 0 | Common Stock | |
| Scynexis Inc | Ann F. Hanham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 2,875 | 2,875 | - | - | Stock Option (Right to Buy) | |
| Scynexis Inc | Brian Philippe Tinmouth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2026 | 2,875 | 2,875 | - | - | Stock Option (Right to Buy) |
This section tracks all disclosures required by the U.S. Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934, particularly those related to Section 16 and Rule 10b-5, which govern insider trading activities in the U.S. market. These disclosures are made by corporate insiders, including executives, officers, directors, significant employees, and large shareholders, who are buying and selling stock in their own companies. You can search and filter within these results. You can also sort the information by clicking on the column headers.